Wesley Blackaby

Wesley Blackaby is currently the Head of Chemistry for global Chemistry and Analytical Sciences at Servier since February 2021. In addition, Wesley serves as a Scientific Advisor at STORM Therapeutics Limited, a spin-out from the University of Cambridge focused on small molecule drugs targeting RNA-modifying enzymes. Previous roles include Vice President of Chemistry at Charles River Laboratories from April 2014 to March 2017, and Senior Director at BioFocus from January 2006 to April 2014. Wesley's early career at Merck Sharp & Dohme spanned from January 1996 to January 2006, where the titles held included Senior Research Chemist. Wesley earned a PhD in Chemistry from Cardiff University and a BSc in Chemistry from the University of Southampton.